Drug intelligence / Profile preview

5LGr

Development stage: Unknown
Lead developer: Tasly Pharmaceuticals, Inc.
Administration: Oral

Overview

5LGr is a drug developed by Tasly Pharmaceuticals, Inc. It is currently in a Phase III clinical trial to evaluate its effectiveness and safety in pediatric patients with tic disorders. The drug is administered orally in granule form. The specific mechanism of action for 5LGr is not publicly available.

Beyond the preview

Go deeper on 5LGr.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5LGr.

Explore the full profile